INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 56 filers reported holding INOZYME PHARMA INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $68,183 | +113.1% | 16,234 | +107.9% | 0.00% | – |
Q1 2022 | $32,000 | -46.7% | 7,810 | -10.5% | 0.00% | – |
Q4 2021 | $60,000 | -37.5% | 8,728 | +5.5% | 0.00% | – |
Q3 2021 | $96,000 | -34.2% | 8,276 | -3.1% | 0.00% | – |
Q2 2021 | $146,000 | -7.0% | 8,542 | +7.7% | 0.00% | – |
Q1 2021 | $157,000 | +23.6% | 7,933 | +29.1% | 0.00% | – |
Q4 2020 | $127,000 | +9.5% | 6,146 | +38.7% | 0.00% | – |
Q3 2020 | $116,000 | – | 4,430 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |